---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-019295"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:34:38.228441+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ADMA Q1 revenue flat at $114.5M, ASCENIV up 28%; withdraws long-term guidance

## Summary
- Revenue $114.5M flat YoY; ASCENIV rev $97.5M (+28%) offset by BIVIGAM -54%.
- GAAP net income $45.3M (+68%); Adjusted net income $40.7M (+22%); Adjusted EBITDA $59.7M (+24%).
- FY 2026 guidance: rev $530-560M, Adj EBITDA $265-300M; withdraws long-term guidance due to market dynamics.
- Audit committee review found no improper channel stuffing or undisclosed related-party transactions.
- Cash from ops $58M; gross margin expanded to 71% from 53% on product mix shift.

## SEC filing metadata
- accession: 0001140361-26-019295
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/0001140361-26-019295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/ef20072554_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-019295
- JSON: https://secwatch.observer/filing/0001140361-26-019295.json
- Plain text: https://secwatch.observer/filing/0001140361-26-019295.txt

## Source-grounded claims
- claim_id: 42c4759ff59dbcab36661a81448bebd6845c98c1
  claim: ADMA BIOLOGICS, INC. reported three months ended March 31, 2026 results: revenue $114.5 Million, net income Adjusted Net Income (1) of $40.7 Million.
  evidence_excerpt: --- EX-99.1 2 ef20072554_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update 1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income (1) of $40.7 Million, 22% Year-Over-Year Growth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/0001140361-26-019295-index.htm
- claim_id: 6b7bea8aced1778457c2cd10cbcefdef5f833437
  claim: ADMA BIOLOGICS, INC. reported FY 2026 results: revenue $530 million to $560 million, net income $170 million to $200 million. Guidance initiated.
  evidence_excerpt: FY 2026 total revenue expected to be $530 million to $560 million • FY 2026 Adjusted Net Income expected to be $170 million to $200 million • FY 2026 Adjusted EBITDA expected to be $265 million to $300 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/0001140361-26-019295-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.